Non‐invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer

Tumour neoangiogenesis can be assessed non‐invasively by measuring angiogenic cytokine concentrations in peripheral circulation and by dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI). The aim of this study was to assess whether these methods can predict and monitor response to treatment in patients with rectal cancer treated with preoperative chemoradiotherapy.

[1]  E Protopapa,et al.  Vascular density and the response of breast carcinomas to mastectomy and adjuvant chemotherapy. , 1993, European journal of cancer.

[2]  P. Tofts.  Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[3]  C. Marth,et al.  Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. , 2000, Anticancer research.

[4]  I. Hirata,et al.  Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. , 2000, Oncology reports.

[5]  S. Eccles,et al.  Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  A. Bergenheim,et al.  Effects of radiotherapy and estramustine on the microvasculature in malignant glioma , 1999, British Journal of Cancer.

[7]  J. Monson,et al.  Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer , 2000, British Journal of Cancer.

[8]  F. Pezzella,et al.  Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  H. Joensuu,et al.  High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.

[10]  T. Allen-Mersh,et al.  Plasma vascular endothelial but not fibroblast growth factor levels correlate with colorectal liver metastasis vascularity and volume , 2000, British Journal of Cancer.

[11]  A R Padhani,et al.  Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics , 1997, Journal of magnetic resonance imaging : JMRI.

[12]  R. Weichselbaum,et al.  Combined effects of angiostatin and ionizing radiation in antitumour therapy , 1998, Nature.

[13]  A. Harris,et al.  Angiogenesis vs. response after combined chemoradiotherapy of squamous cell head and neck cancer , 1999, International journal of cancer.

[14]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[15]  R. Odze,et al.  Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. , 1999, Human pathology.

[16]  S. Kumar,et al.  Prognostic relevance of microvessel density in colorectal tumours. , 1999, Oncology reports.

[17]  R. Weichselbaum,et al.  Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation , 1999 .

[18]  A R Padhani,et al.  In vivo monitoring of tumor angiogenesis with MR imaging. , 2000, Academic radiology.

[19]  Y. Terai,et al.  Apoptosis and tumor angiogenesis in cervical cancer after preoperative chemotherapy. , 1998, Cancer research.

[20]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[21]  S. Ménard,et al.  Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[22]  M. Toi,et al.  Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  S. Hong,et al.  Tumor Angiogenesis as a Prognostic Predictor in Colorectal Carcinoma with Special Reference to Mode of Metastasis and Recurrence , 1998, Oncology.

[24]  H. Joensuu,et al.  A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. , 1997, Blood.

[25]  M V Knopp,et al.  Evaluation of angiogenesis and perfusion of bone marrow lesions: Role of semiquantitative and quantitative dynamic MRI , 1999, Journal of magnetic resonance imaging : JMRI.

[26]  D. Pode,et al.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. , 1999, The Journal of clinical investigation.

[27]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[28]  J. Weyler,et al.  Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer , 1999, British Journal of Cancer.

[29]  C Kremser,et al.  Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. , 2000, Radiology.

[30]  J P Logue,et al.  Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  A. Padhani,et al.  A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[33]  S. Eccles,et al.  VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. , 2001, Neoplasia.

[34]  M V Knopp,et al.  Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  T. Nose,et al.  Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.

[36]  P. Johnston,et al.  Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  S. Akiba,et al.  Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma , 1996, Cancer.